← Back to All Filings

BIO-TECHNE CFO Sells $742K in Stock for Tax Withholding

Low SignificanceNovember 5, 2025 at 5:03:03 PM EST

BIO-TECHNE Corp

$TECH4CIK: 0000842023

Subscribe to track TECH

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

BIO-TECHNE CFO Sells $742K in Stock for Tax Withholding

Company: BIO-TECHNE Corp (TECH) Form: 4 | Filed: 2025-11-05 Significance: Low

Insider: Hippel James Title: CFO | Relationship: Officer

Transaction: • Type: Tax Withholding (Sell-to-Cover) • Shares: 11,865 • Price: $62.57 • Value: $742,422 • Owned After: 142,722

Key Insight: This is a non-discretionary sale to cover tax obligations from vested Restricted Stock Units (RSUs). It is not considered a bearish signal of insider sentiment.

Market Context: The transaction represents a negligible percentage of the company's market cap and the insider's total holdings.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: BIO-TECHNE Corp (TECH)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The CFO executed a routine "sell-to-cover" transaction to pay taxes on newly vested Restricted Stock Units (RSUs), which is not indicative of a change in outlook for the company.
  • Market Impact: Negligible. The transaction size is immaterial relative to the company's market capitalization and public float.

Company Information

FieldValue
CompanyBIO-TECHNE Corp
Ticker SymbolTECH
CIK0000842023
IndustryBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

FieldValue
NameHippel James
CIK0001603594
Title/PositionCFO
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-03
Transaction CodeF (Payment of tax liability by withholding securities)
Security TypeCommon Stock
Shares Involved11,865
Price Per Share$62.57
Total Value$742,422.05
Shares Owned After142,722
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$742,422.05
% of Market Cap0.0076%
Shares Transacted11,865
% of Shares Outstanding0.0076%
Post-Transaction Ownership142,722 shares (0.092% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $9.74 billion, this $742k transaction is financially insignificant.
  • Ownership Concentration: The CFO's ownership remains minimal at less than 0.1% of total shares outstanding.
  • Dilution Impact: The underlying vesting of 24,704 RSUs (which prompted this tax sale) represents a minor 0.016% dilution to existing shareholders.
  • Transaction Significance: The sale is classified as a non-discretionary event. The insider acquired a net of 12,839 shares after the vesting and tax sale, which is a minor increase in holdings.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is a routine sell-to-cover action required to satisfy tax liabilities upon RSU vesting. It does not reflect a voluntary decision to reduce exposure to the company's stock.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction is too small to impact trading volume.
  • Sentiment Indicator: Neutral. The market typically disregards 'F' coded transactions as they are not indicative of insider sentiment.

Additional Context

Transaction Notes

  • Special Circumstances: The filing shows the acquisition of 24,704 shares of common stock through the vesting of RSUs (Code 'M') and the simultaneous disposition of 11,865 shares to cover taxes (Code 'F'). This is a standard procedure for equity compensation.
Topics:#SECFiling#InsiderTrading#TECH#BioTechne#Form4#StockAlert#CFO#SellToCover#Investing#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.